Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.74 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 8/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.57 |
| ▸ | CHRNA5 | P30532 | 2/20 | 0.57 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.49 |
| ▸ | MMP9 | P14780 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8698170 | 1.00 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Hydrochloric Acid SCHEMBL8698166 | 1.00 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL2210517 | 0.98 | NPC1 (0.77) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL146883 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28209867 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28209866 | 0.96 | NPC1 (0.74) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28286654 | 0.94 | NPC1 (0.72) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| Bromide SCHEMBL28286655 | 0.94 | NPC1 (0.72) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL23625647 | 0.94 | NPC1 (0.71) | NPC1ABCG2RAB9ACHRNB2CHRNA5 | |
| SCHEMBL23625628 | 0.92 | NPC1 (0.69) | NPC1ABCG2RAB9ACHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5059526-A | Storage stability, accuracy | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1991-10-22 | — | — | US | claimed |
| CN-108700503-B | Biometric identification system | 泰斯科有限公司 | 2021-12-03 | — | — | CN | disclosed |
| CN-107923838-B | Biological material measuring instrument | 泰斯科有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-111575339-A | 1, 5-anhydroglucitol enzymatic quantitative method and reagent therefor | 王学忠 | 2020-08-25 | — | — | CN | disclosed |
| US-9925191-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2018-03-27 | — | — | US | disclosed |
| US-9630934-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-04-25 | — | — | US | disclosed |
| US-9598354-B2 | Fumarate compounds, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-03-21 | — | — | US | disclosed |
| US-20170065571-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | ARES TRADING S.A. (CH) | 2017-03-09 | — | — | US | disclosed |
| US-20170056358-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-03-02 | — | — | US | disclosed |
| WO-2017023445-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20020045573-A1 | POLYDITHIOCARBAMATE-CONTAINING NON-TARGETING MACROMOLECULES AND THE USE THEREOF FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS | LAI CHING-SAN (US) | 2002-04-18 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0804183-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENDA GROUP, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996014063-A1 | USE OF CREATINE OR CREATINE ANALOGS FOR THE TREATMENT OF DISEASES OF THE NERVOUS SYSTEM | AVICENA GROUP, INC. (US) | 1996-05-17 | — | — | WO | disclosed |
| EP-0272518-B1 | Analytical element for measuring enzyme activity | FUJI PHOTO FILM CO LTD (JP) | 1994-04-13 | — | — | EP | disclosed |
| EP-0480676-A2 | Acyl carnitine esterase, production thereof and method for analyzing acyl carnitines | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1992-04-15 | — | — | EP | disclosed |
| US-5006458-A | Accuracy | FUJI PHOTO FILM CO., LTD. (JP) | 1991-04-09 | — | — | US | disclosed |
| EP-0272518-A2 | Analytical element for measuring enzyme activity | Fuji Photo Film Co., Ltd. (JP) | 1988-06-29 | — | — | EP | disclosed |
| EP-0258862-A2 | Method for measuring concentration or activity of specific component in liquid to be tested | KONICA CORPORATION (JP) | 1988-03-09 | — | — | EP | disclosed |
| US-4693971-A | Highly sensitive enzyme assay method | TOYO JOZO KABUSHIKI KAISHA (JP) | 1987-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170065571-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING GLITAZONES AND NRF2 ACTIVATORS | PPARG, PPARA, PPARD | NPC1 1750/4885ABCG2 187/4885RAB9A 3658/4885 |
| US-20170056358-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | NPC1 2073/4885ABCG2 618/4885RAB9A 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.